Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Aug. 22, 2018. Gary Altman.

Executive Summary

Scottsdale, Ariz.-based Provista Diagnostics is looking at breast cancer with a focus on early detection. The manufacturer's Videssa assay aims to rule out breast cancer in women with both dense and non-dense breast tissue, and the firm is providing guidance to physicians in cases where imaging modalities are inconclusive. See what Provista CEO Gary Altman said about it here.

"There are many blood tests out there that indicate they are looking at breast cancer, but many of them are risk factors. Ours is the only one that we are aware of which interrogates proteins, tumor auto-antibodies and serum biomarkers to indicate with a great deal of accuracy the presence of active breast cancer. It is especially useful for women with dense breast tissue for which the radiologists have difficulty interpreting the image or with other women of high risk, that is [with] genomic factors or familial history." – Gary Altman, CEO, Provista Diagnostics Inc.

Click here for a free trial of Medtech Insight


Related Content

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts